SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2019
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
4275 EXECUTIVE SQUARE,
SUITE 300, LA JOLLA, CA
|(Address of principal executive offices)||(Zip Code)|
Registrants telephone number, including area code: (858) 373-1500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Common Stock, $0.001 par value
The Nasdaq Stock Market LLC
|(Title of each class)||(Trading symbol(s))||
(Name of each exchange on
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 24, 2019, the Board of Directors (the Board) of MediciNova, Inc. (the Company) authorized and appointed Dr. Kazuko Matsuda as a member of the Board as a Class II director, effective immediately. The Company issued a press release announcing the appointment of Dr. Matsuda, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.
There are no family relationships between Dr. Matsuda and any of the Companys directors or executive officers and Dr. Matsuda does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There were no arrangements or understandings by which Dr. Matsuda was named a director.
Financial Statements and Exhibits.
|99.1||Press Release Issued by the Company on July 24, 2019 announcing the appointment of Dr. Kazuko Matsuda to the Board of Directors.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|DATE: July 25, 2019||By:||/s/ Carla Reyes|
|Chief Financial Officer|
MediciNova Appoints Kazuko Matsuda to its Board of Directors
LA JOLLA, Calif., July 24, 2019 (GLOBE NEWSWIRE) MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Dr. Kazuko Matsuda to its Board of Directors.
Dr. Matsuda received her M.D. and Ph.D. from Sapporo Medical School in Japan, and Master of Public Health from Harvard University, School of Public Health, in the U.S. She is a board-certified pediatrician in both the United States and Japan. Dr. Matsuda, in her capacity as Chief Medical Officer for MediciNova since 2013, has demonstrated time and again strong leadership skills and creativity culminating in the advancement of MediciNovas promising clinical drug development programs. These qualities make her an excellent choice for membership on MediciNovas Board of Directors.
We are extremely pleased and fortunate to add an individual with such strong clinical research expertise to MediciNovas Board of Directors, said Yuichi Iwaki, M.D., Ph.D., MediciNovas President and Chief Executive Officer. We believe Dr. Matsuda will be a great asset to the Company and its shareholders.
MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a primary commercial focus on the U.S. market. MediciNovas current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), degenerative cervical myelopathy (DCM), substance dependence (e.g., alcohol use disorder, methamphetamine dependence, opioid dependence) and glioblastoma (GBM), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNovas pipeline also includes MN-221 (bedoradrine) and MN-029 (denibulin). For more information on MediciNova, Inc., please visit www.medicinova.com .
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements
may be preceded by, followed by or otherwise include the words believes, expects, anticipates, intends, estimates, projects, can, could, may, will, would, considering, planning or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNovas operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNovas collaborations with third parties, the availability of funds to complete product development plans and MediciNovas ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNovas filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2018 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.